Seres Therapeutics (MCRB)
NASDAQ:MCRB
Want to see MCRB full AI Analyst Report?
MCRB Stock Chart & Stats
$8.89
>-$0.01(-0.25%)
At close: 4:00 PM EST
$8.89
>-$0.01(-0.25%)
Day’s Range― - ―
52-Week Range$6.53 - $29.98
Previous CloseN/A
Volume457.00K
Average Volume (3M)45.86K
Market Cap
$77.55M
Enterprise Value$114.85M
Total Cash (Recent Filing)$45.77M
Total Debt (Recent Filing)$82.97M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 13, 2026EPS Estimate
-1.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding9,586,298
10 Day Avg. Volume44,972
30 Day Avg. Volume45,862
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)2.98
Price to Sales (P/S)167.07
P/FCF Ratio152.39
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue145.56
Enterprise Value/Gross Profit-34.34
Enterprise Value/Ebitda16.45
Forecast
1Y Price Target
$21.00Price Target Upside136.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ReadinessFinalized Phase 2 protocol submission for SER-155 enables a potential partner to begin development quickly and increases the program's attractiveness for collaboration.
Leadership And PartnershipsAppointment of an experienced CEO with long board tenure could help secure strategic partnerships to advance SER-155 development.
Pipeline Strategy For IBDRefocusing on SER-603, an IBD candidate designed to improve gut mucosal barrier integrity as a non-immunosuppressive option, offers a differentiated approach that may draw partner and investor interest.
Bears Say
Financing RiskLimited cash resources create a need to secure additional funding, posing a financing risk to the advancement of clinical programs.
Program Development DelayPausing internal investment in the allogeneic stem cell transplantation program while a partnership search continues delays internal advancement and could reduce near-term pipeline value.
Seres Therapeutics News
MCRB FAQ
What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $6.53 and its highest was $29.98 in the past 12 months.
What is Seres Therapeutics’s market cap?
Seres Therapeutics’s market cap is $77.55M.
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 18 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Mar 12, 2026. The company reported -$1.78 earnings per share for the quarter, beating the consensus estimate of -$2.11 by $0.33.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is -1.88.
How many shares outstanding does Seres Therapeutics have?
Seres Therapeutics has 9,586,298 shares outstanding.
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of -$1.78 in its last earnings report, beating expectations of -$2.11. Following the earnings report the stock price went up 1.344%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Currently, no hedge funds are holding shares in MCRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seres Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (136.22% Upside)
$21.00 (136.22% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.13%
12-Months-Change
Fundamentals
Return on Equity
13.30%
Trailing 12-Months
Asset Growth
-1.16%
Trailing 12-Months
Company Description
Seres Therapeutics
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
MCRB Stock 12 Month Forecast
Average Price Target
$21.00
▲(136.22% Upside)
Technical Analysis
Anixa Biosciences
―
Surrozen
―
Cognition Therapeutics
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
1.07% Insiders
4.33% Mutual Funds
13.23% Other Institutional Investors
77.00% Public Companies and
Individual Investors